Enalapril in heart failure.
Serum MK-422 and plasma angiotensin converting enzyme activity were measured during the introduction of enalapril therapy in eight patients with heart failure. In a second study of 16 patients, we recorded exercise tolerance, clinical status and haemodynamics before and after 12 weeks of placebo or enalapril treatment. Increasing doses of enalapril gave step-wise increments in serum MK-422. Plasma converting enzyme activity remained low for at least 24 h after each dose of enalapril (5, 10 and 20 mg). Compared to placebo patients (n = 8), those receiving enalapril (n = 8) tended to improve their exercise performance and clinical status, and showed a fall in right heart pressures after 12 weeks of treatment.
D000368:Aged; D002986:Clinical Trials as Topic; D004151:Dipeptides / Q000097:blood / Q000627:therapeutic use*; D004311:Double-Blind Method; D004656:Enalapril; D015773:Enalaprilat; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005080:Exercise Test; D006333:Heart Failure / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D008875:Middle Aged; D007703:Peptidyl-Dipeptidase A / Q000097:blood
D004151:Dipeptides; D004791:Enzyme Inhibitors; D004656:Enalapril; D007703:Peptidyl-Dipeptidase A; D015773:Enalaprilat